NL7605382A
(nl)
*
|
1975-06-04 |
1976-12-07 |
Sumitomo Chemical Co |
Werkwijze voor het bereiden van indoolderivaten.
|
JPS5328173A
(en)
*
|
1976-08-06 |
1978-03-16 |
Zenyaku Kogyo Kk |
Novel phenylmethanenitro compound and its preparation
|
DE2735133C2
(de)
|
1977-08-04 |
1981-10-15 |
Universität Karlsruhe Institut für Elektrotechnische Grundlagen der Informatik, 7500 Karlsruhe |
Speicherzelle für zerstörungsfreies Auslesen mit 2 Josephson-Kontakten
|
US4138397A
(en)
*
|
1978-02-27 |
1979-02-06 |
Richardson-Merrell Inc. |
6-(2,3-Dihydro-5-benzofuranyl)acetamido penicillin derivatives
|
GB8524157D0
(en)
|
1984-10-19 |
1985-11-06 |
Ici America Inc |
Heterocyclic amides
|
JPS61103861A
(ja)
*
|
1984-10-27 |
1986-05-22 |
Nitto Kasei Kk |
アリ−ル置換シアン酢酸エステルの製造方法
|
US5304121A
(en)
|
1990-12-28 |
1994-04-19 |
Boston Scientific Corporation |
Drug delivery system making use of a hydrogel polymer coating
|
US5716981A
(en)
|
1993-07-19 |
1998-02-10 |
Angiogenesis Technologies, Inc. |
Anti-angiogenic compositions and methods of use
|
GB9317764D0
(en)
|
1993-08-26 |
1993-10-13 |
Pfizer Ltd |
Therapeutic compound
|
US5510379A
(en)
|
1994-12-19 |
1996-04-23 |
Warner-Lambert Company |
Sulfonate ACAT inhibitors
|
US6099562A
(en)
|
1996-06-13 |
2000-08-08 |
Schneider (Usa) Inc. |
Drug coating with topcoat
|
JPH10213820A
(ja)
|
1997-01-31 |
1998-08-11 |
Canon Inc |
液晶素子及び液晶装置
|
WO1998047868A1
(fr)
|
1997-04-18 |
1998-10-29 |
Smithkline Beecham Plc |
Derives d'uree contenant un heterocycle utilises comme antagonistes des recepteurs 5ht1a, 5ht1b et 5ht¿1d?
|
CA2294259A1
(fr)
*
|
1997-06-21 |
1998-12-30 |
Roche Diagnostics Gmbh |
Derives d'acide barbiturique dotes d'une activite antimetastatique et anitumorale
|
PT901786E
(pt)
|
1997-08-11 |
2007-08-07 |
Pfizer Prod Inc |
Disperções farmacêuticas sólidas com biodisponibilidade melhorada
|
US20020017295A1
(en)
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
CN1283995A
(zh)
|
1997-12-11 |
2001-02-14 |
生化制药有限公司 |
抗病毒化合物
|
US6426331B1
(en)
|
1998-07-08 |
2002-07-30 |
Tularik Inc. |
Inhibitors of STAT function
|
AUPP609198A0
(en)
|
1998-09-22 |
1998-10-15 |
Curtin University Of Technology |
Use of non-peptidyl compounds for the treatment of insulin related ailments
|
EP1035115B1
(fr)
|
1999-02-24 |
2004-09-29 |
F. Hoffmann-La Roche Ag |
Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1
|
ATE309250T1
(de)
|
1999-09-10 |
2005-11-15 |
Novo Nordisk As |
Modulatoren der protein tyrosin phosphatase (ptpases)
|
DE60028791T2
(de)
|
1999-09-10 |
2007-05-24 |
Novo Nordisk A/S |
Modulatoren der protein tyrosin phosphatase (ptpases)
|
AUPQ288499A0
(en)
|
1999-09-16 |
1999-10-07 |
Biota Scientific Management Pty Ltd |
Antiviral agents
|
US6514964B1
(en)
|
1999-09-27 |
2003-02-04 |
Amgen Inc. |
Fused cycloheptane and fused azacycloheptane compounds and their methods of use
|
IT1315267B1
(it)
|
1999-12-23 |
2003-02-03 |
Novuspharma Spa |
Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
|
TWI284639B
(en)
|
2000-01-24 |
2007-08-01 |
Shionogi & Co |
A compound having thrombopoietin receptor agonistic effect
|
DE10038019A1
(de)
*
|
2000-08-04 |
2002-02-14 |
Bayer Ag |
Substituierte Triazolopyrid(az)ine
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US6562989B2
(en)
*
|
2000-08-07 |
2003-05-13 |
Yale University |
Catalyst for aromatic C—O, C—N, and C—C bond formation
|
TWI259180B
(en)
|
2000-08-08 |
2006-08-01 |
Hoffmann La Roche |
4-Phenyl-pyridine derivatives
|
AR030357A1
(es)
|
2000-08-18 |
2003-08-20 |
Lundbeck & Co As H |
Derivados 4 -, 5 -, 6 - y 7-indol
|
NZ525324A
(en)
|
2000-10-20 |
2005-03-24 |
Eisai Co Ltd |
Nitrogenous aromatic ring compounds
|
US6550895B1
(en)
|
2000-10-20 |
2003-04-22 |
Silverbrook Research Pty Ltd |
Moving nozzle ink jet with inlet restriction
|
EP1217000A1
(fr)
|
2000-12-23 |
2002-06-26 |
Aventis Pharma Deutschland GmbH |
Inhibiteurs du factor Xa et factor VIIa
|
GB0102109D0
(en)
|
2001-01-26 |
2001-03-14 |
Syngenta Ltd |
Chemical process
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
WO2003084997A1
(fr)
|
2001-04-10 |
2003-10-16 |
Transtech Pharma, Inc. |
Sondes, systemes et procedes pour la decouverte de medicaments
|
ATE449763T1
(de)
|
2001-04-16 |
2009-12-15 |
Eisai R&D Man Co Ltd |
1h-indazolverbindungen die jnk hemmen
|
OA12626A
(en)
|
2001-06-28 |
2006-06-13 |
Pfizer Prod Inc |
triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP)and/or apolipoprotein B(APO B) secretion.
|
WO2003007945A1
(fr)
|
2001-07-20 |
2003-01-30 |
Boehringer Ingelheim (Canada) Ltd. |
Inhibiteurs de polymerase virale
|
AUPR738301A0
(en)
|
2001-08-30 |
2001-09-20 |
Starpharma Limited |
Chemotherapeutic agents
|
JP4343690B2
(ja)
|
2001-11-13 |
2009-10-14 |
メルク フロスト カナダ リミテツド |
プロテアーゼ阻害薬としてのシアノアルキルアミノ誘導体
|
RU2374236C2
(ru)
|
2001-12-21 |
2009-11-27 |
Ново Нордиск А/С |
Амидные производные в качестве активаторов gk
|
US7074805B2
(en)
|
2002-02-20 |
2006-07-11 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
US20030158188A1
(en)
|
2002-02-20 |
2003-08-21 |
Chih-Hung Lee |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
AU2003228744A1
(en)
|
2002-04-29 |
2003-11-17 |
The Ohio State University |
Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
|
BR0312023A
(pt)
|
2002-06-27 |
2005-03-22 |
Novo Nordisk As |
Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
|
WO2004007472A1
(fr)
|
2002-07-10 |
2004-01-22 |
Ono Pharmaceutical Co., Ltd. |
Antagoniste du ccr4 et utilisation medicinale correspondante
|
TWI244393B
(en)
|
2002-08-06 |
2005-12-01 |
Idenix Pharmaceuticals Inc |
Crystalline and amorphous forms of beta-L-2'-deoxythymidine
|
CA2497903A1
(fr)
|
2002-09-18 |
2004-04-01 |
Ono Pharmaceutical Co., Ltd. |
Derives triazaspiro[5.5]undecanes et medicaments les contenant en tant que principe actif
|
KR20050061501A
(ko)
|
2002-09-30 |
2005-06-22 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
낭종 섬유증 트랜스막 전도도 조절기 단백질 억제제 및이의 용도
|
JP2004131393A
(ja)
|
2002-10-08 |
2004-04-30 |
Kowa Co |
易溶出性製剤
|
US20050215614A1
(en)
|
2002-10-15 |
2005-09-29 |
Rigel Pharmaceuticals, Inc. |
Substituted indoles and their use as hcv inhibitors
|
FR2846327B1
(fr)
*
|
2002-10-25 |
2006-03-24 |
Merck Sante Sas |
Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
|
US7622592B2
(en)
|
2002-11-01 |
2009-11-24 |
Merck & Co., Inc. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
DE10251019A1
(de)
|
2002-11-02 |
2004-05-19 |
Aventis Pharma Deutschland Gmbh |
Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen
|
JP4564359B2
(ja)
|
2002-11-02 |
2010-10-20 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
選択的にコラゲナーゼを阻害する新規ピリミジン−4,6−ジカルボン酸ジアミド
|
US20040146941A1
(en)
|
2002-11-04 |
2004-07-29 |
Biliang Zhang |
Chemical encoding technology for combinatorial synthesis
|
WO2004056744A1
(fr)
|
2002-12-23 |
2004-07-08 |
Janssen Pharmaceutica N.V. |
Adamantyl acetamides utilises comme inhibiteurs de la hydroxysteroide deshydrogenase
|
DE10300017A1
(de)
|
2003-01-03 |
2004-07-15 |
Aventis Pharma Deutschland Gmbh |
Selektive MMP 13 Inhibitoren
|
US20040229955A1
(en)
|
2003-01-08 |
2004-11-18 |
Andersen Niels H. |
Antibacterial agents
|
US6933311B2
(en)
|
2003-02-11 |
2005-08-23 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
DE602004024375D1
(de)
|
2003-02-14 |
2010-01-14 |
Glaxo Group Ltd |
Carboxamidderivate
|
DE10306941A1
(de)
|
2003-02-18 |
2004-08-26 |
Merck Patent Gmbh |
Benzofuranoxyethylamine
|
EP1601657A1
(fr)
|
2003-03-12 |
2005-12-07 |
Vertex Pharmaceuticals Incorporated |
Pyrazoles, modulateurs de transporteurs de cassettes de liaison a l'atp
|
EP1720844B1
(fr)
|
2003-04-03 |
2009-04-29 |
MERCK PATENT GmbH |
Derives pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl9-phenylamide) et composes similaires pour l'utilisation comme inhibiteurs du facteur xa pour le traitement de maladies thromboemboliques
|
DE10315377A1
(de)
|
2003-04-03 |
2004-10-14 |
Merck Patent Gmbh |
Carbonylverbindungen
|
US20050164951A1
(en)
|
2003-04-03 |
2005-07-28 |
The Regents Of The University Of California |
Inhibitors for the soluble epoxide hydrolase
|
PL3632902T3
(pl)
|
2003-04-11 |
2021-12-20 |
Ptc Therapeutics, Inc. |
Związek kwasu 1,2,4-oksadiazolobenzoesowego i jego zastosowanie do supresji mutacji nonsensownych i leczenia choroby
|
ATE482747T1
(de)
|
2003-04-11 |
2010-10-15 |
High Point Pharmaceuticals Llc |
Neue amide derivate und deren pharmazeutische verwendungen
|
WO2004110352A2
(fr)
|
2003-05-16 |
2004-12-23 |
The Regents Of The University Of California |
Composes accroissant le transport d'ions par des cftr de mutants, et leurs utilisations
|
DE602004022819D1
(de)
|
2003-06-06 |
2009-10-08 |
Vertex Pharma |
Von atp-bindende kassette transportern
|
EP1638505B1
(fr)
|
2003-06-27 |
2012-04-25 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Composes de pyridinium amphiphiles, leurs procedes de fabrication et d'utilisation
|
US20050113576A1
(en)
|
2003-08-05 |
2005-05-26 |
Chih-Hung Lee |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
BRPI0413584A
(pt)
|
2003-08-15 |
2006-10-17 |
Lundbeck & Co As H |
composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de doenças e para tratamento de um distúrbio no sistema nervoso central
|
CA2537841A1
(fr)
|
2003-09-06 |
2005-03-24 |
Vertex Pharmaceuticals Incorporated |
Modulateurs de transporteurs a cassette de liaison a l'atp
|
US20050070718A1
(en)
|
2003-09-30 |
2005-03-31 |
Abbott Gmbh & Co. Kg |
Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
|
WO2005035514A2
(fr)
|
2003-10-08 |
2005-04-21 |
Vertex Pharmaceuticals Incorporated |
Modulateurs des transporteurs des cassettes de fixation de l'atp
|
WO2005037802A1
(fr)
*
|
2003-10-16 |
2005-04-28 |
Sankyo Company, Limited |
Derive de 5-arylpyrimidine
|
EP1679309A4
(fr)
|
2003-10-24 |
2007-03-28 |
Ono Pharmaceutical Co |
Medicament antistress et usage medical correspondant
|
CA2545719A1
(fr)
|
2003-11-14 |
2005-06-02 |
Vertex Pharmaceuticals Incorporated |
Thiazoles et oxazoles utiles en tant que modulateurs de transporteurs de type cassette de liaison a l'atp
|
GB0330043D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
EP1716122B1
(fr)
|
2004-01-30 |
2017-04-19 |
Vertex Pharmaceuticals Incorporated |
Modulateurs de transporteurs de type cassette de liaison a l'atp
|
BRPI0507159A
(pt)
|
2004-02-02 |
2007-06-26 |
Ambrx Inc |
polipeptìdeos em feixe de quatro hélices humanos modificados e seus usos
|
WO2005094374A2
(fr)
|
2004-03-30 |
2005-10-13 |
The Regents Of The University Of California |
Composes inhibiteurs de cftr contenant des hydrazides et utilisations de ceux-ci
|
US20050222271A1
(en)
|
2004-03-31 |
2005-10-06 |
Le Huang |
Novel amorphous form of memantine hydrochloride
|
FR2868417B1
(fr)
|
2004-04-02 |
2006-06-23 |
Rhodia Chimie Sa |
Procede de formation d'une liaison carbone-carbone
|
EP1766062A4
(fr)
|
2004-06-01 |
2008-07-09 |
Tm Bioscience Corp |
Procédé de détection des mutations associées à la fibrose cystique
|
WO2005120497A2
(fr)
|
2004-06-04 |
2005-12-22 |
The Regents Of The University Of California |
Composes intervenant dans l'acceleration du transport ionique par le cftr mutant, et utilisations desdits composes
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
CN107501099B
(zh)
|
2004-06-24 |
2021-03-19 |
沃泰克斯药物股份有限公司 |
Atp-结合弹夹转运蛋白的调控剂
|
US20140343098A1
(en)
|
2004-06-24 |
2014-11-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
EP1771158A4
(fr)
|
2004-07-02 |
2008-03-12 |
Advancis Pharmaceutical Corp |
Comprimé pour distribution par impulsion
|
GB0416730D0
(en)
|
2004-07-27 |
2004-09-01 |
Novartis Ag |
Organic compounds
|
AU2005268030B2
(en)
|
2004-08-06 |
2009-02-19 |
Otsuka Pharmaceutical Co., Ltd. |
Aromatic compounds
|
DE102004047254A1
(de)
|
2004-09-29 |
2006-04-13 |
Merck Patent Gmbh |
Carbonylverbindungen
|
EP2311455B1
(fr)
|
2004-10-13 |
2015-07-15 |
PTC Therapeutics, Inc. |
Composes de suppression de non-sens et procedes de leur utilisation
|
EP1814875A4
(fr)
|
2004-10-20 |
2010-02-17 |
Univ California |
Inhibiteurs ameliores de l'epoxyde hydrolase soluble
|
JPWO2006057448A1
(ja)
|
2004-11-26 |
2008-06-05 |
武田薬品工業株式会社 |
アリールアルカン酸誘導体
|
JP5024039B2
(ja)
|
2005-02-25 |
2012-09-12 |
小野薬品工業株式会社 |
インドール化合物およびその用途
|
EP2363128B1
(fr)
|
2005-03-11 |
2016-02-17 |
Vertex Pharmaceuticals Incorporated |
Indoles, modulateurs des transporteurs de la cassette de liaison à l ATP
|
KR20070114820A
(ko)
|
2005-03-18 |
2007-12-04 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
돌연변이-cftr 처리를 보정하는데 활성을 가지는화합물 및 이것의 사용
|
GB0506133D0
(en)
|
2005-03-24 |
2005-05-04 |
Sterix Ltd |
Compound
|
US20100120789A1
(en)
|
2005-03-24 |
2010-05-13 |
Nigel Vicker |
Compound
|
US7297700B2
(en)
|
2005-03-24 |
2007-11-20 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
SI2248809T1
(sl)
|
2005-03-28 |
2012-09-28 |
Toyama Chemical Co Ltd |
Alkil-3-(2-(benzo(b)tiofen-5-il)-etoksi)-propanoati kot vmesniki v proizvodnji derivatov azetidin-3-ola
|
JP2006282534A
(ja)
|
2005-03-31 |
2006-10-19 |
Fuji Photo Film Co Ltd |
アミド類の製造方法
|
DK1874306T3
(da)
|
2005-04-08 |
2012-10-01 |
Ptc Therapeutics Inc |
Sammensætninger af en oralt aktiv 1,2,4-oxadiazol til nonsens-mutationssuppressionsterapi
|
EP1877401A2
(fr)
|
2005-04-15 |
2008-01-16 |
Elan Pharmaceuticals Inc. |
Nouveaux composes s'utilisant dans l'antagonisme du recepteur de bradykinine b1
|
US8822451B2
(en)
|
2005-05-24 |
2014-09-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
ZA200802172B
(en)
|
2005-08-11 |
2009-06-24 |
Vertex Pharma |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2007021982A2
(fr)
|
2005-08-11 |
2007-02-22 |
Vertex Pharmaceuticals Incorporated |
Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
|
JP2009510066A
(ja)
*
|
2005-09-29 |
2009-03-12 |
ワイス |
血管運動症状(vms)の治療のためのモノアミン再取り込みのモジュレータである1−(1h−インドール−1−イル)−3−(メチルアミノ)−1−フェニルプロパン−2−オール誘導体および関連の化合物
|
CA2624683A1
(fr)
|
2005-10-06 |
2007-04-19 |
Vertex Pharmaceuticals Incorporated |
Modulateurs de transporteurs de cassette de liaison a l'atp
|
US20070219192A1
(en)
|
2005-11-02 |
2007-09-20 |
Xiangping Qian |
Certain chemical entities, compositions, and methods
|
EP2395002B1
(fr)
|
2005-11-08 |
2014-06-18 |
Vertex Pharmaceuticals Inc. |
Composition pharmaceutique contenant un modulateur hétérocyclique de transporteurs de cassette à liaison atp
|
US20120232059A1
(en)
|
2005-11-08 |
2012-09-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette Transporters
|
GB0525144D0
(en)
|
2005-12-09 |
2006-01-18 |
Novartis Ag |
Organic compounds
|
MY159523A
(en)
|
2005-12-21 |
2017-01-13 |
Janssen Pharmaceutica Nv |
Triazolopyridazines as tyrosine kinase modulators
|
CN101374849A
(zh)
|
2005-12-24 |
2009-02-25 |
沃泰克斯药物股份有限公司 |
作为abc转运蛋白调控剂的喹啉-4-酮衍生物
|
WO2007075946A1
(fr)
|
2005-12-27 |
2007-07-05 |
Vertex Pharmaceuticals Incorporated |
Composes utiles dans les bio-essais cftr et leurs procedes
|
PL1993360T3
(pl)
|
2005-12-28 |
2017-08-31 |
Vertex Pharmaceuticals Incorporated |
Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
|
US7671221B2
(en)
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
EP2016065B1
(fr)
|
2005-12-28 |
2012-09-19 |
Vertex Pharmaceuticals Incorporated |
Dérivés de la 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide et composés similaires en tant que modulateurs des transporteurs de cassettes de liaison de l'atp pour le traitement de la fibrose cystique
|
AR059826A1
(es)
|
2006-03-13 |
2008-04-30 |
Univ California |
Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
|
AU2007226984B2
(en)
|
2006-03-20 |
2013-02-21 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
CN101494979A
(zh)
|
2006-03-20 |
2009-07-29 |
沃泰克斯药物股份有限公司 |
药物组合物
|
EP2001897A2
(fr)
|
2006-03-22 |
2008-12-17 |
Syndexa Pharmaceuticals Corporation |
Composés et méthodes pour traitement de troubles associés à un stress du réticulum endoplasmique
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
RU2451018C2
(ru)
|
2006-04-07 |
2012-05-20 |
Вертекс Фармасьютикалз Инкорпорейтед |
Модуляторы атф-связывающих кассетных транспортеров
|
CN101478964B
(zh)
|
2006-05-12 |
2012-02-29 |
沃泰克斯药物股份有限公司 |
N-[2,4-双(1,1-二甲基乙基)-5-羟苯基]-1,4-二氢-4-氧代喹啉-3-羧酰胺的组合物
|
EP2035005A4
(fr)
|
2006-06-09 |
2011-07-06 |
Kemia Inc |
Thérapie à base d'inhibiteurs de cytokine
|
WO2008020227A2
(fr)
|
2006-08-17 |
2008-02-21 |
Astrazeneca Ab |
Composés chimiques
|
WO2008029168A2
(fr)
|
2006-09-08 |
2008-03-13 |
Summit Corporation Plc |
Traitement de la dystrophie musculaire de duchenne
|
WO2008029152A2
(fr)
|
2006-09-08 |
2008-03-13 |
Summit Corporation Plc |
Traitement de la dystrophie musculaire de duchenne
|
BRPI0717317A2
(pt)
|
2006-10-23 |
2013-10-22 |
Sgx Pharmaceuticals Inc |
Modularoes da proteína cinase triazalopiridazina
|
CN103159760B
(zh)
|
2006-11-03 |
2016-06-08 |
沃泰克斯药物股份有限公司 |
作为cftr调控剂的氮杂吲哚衍生物
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
US7754739B2
(en)
|
2007-05-09 |
2010-07-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
WO2008064259A2
(fr)
|
2006-11-21 |
2008-05-29 |
Biokey, Inc. |
Composition de dispersion solide
|
JPWO2008065732A1
(ja)
|
2006-11-27 |
2010-03-04 |
日本ポリウレタン工業株式会社 |
アロファネート結合及びイソシアヌレート結合含有変性イソシアネート混合物の製造方法
|
US20080260820A1
(en)
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
AU2008251504B2
(en)
|
2007-05-09 |
2013-07-18 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
HUE025553T2
(en)
|
2007-05-25 |
2016-02-29 |
Vertex Pharma |
CFTR modulators
|
US8557823B2
(en)
|
2007-06-18 |
2013-10-15 |
Advanced Cancer Therapeutics, Llc |
Family of PFKFB3 inhibitors with anti-neoplastic activities
|
JP2010531304A
(ja)
|
2007-06-18 |
2010-09-24 |
ユニバーシティ オブ ルイビル リサーチ ファウンデーション、インコーポレイテッド |
抗悪性腫瘍活性を有するpfkfb3阻害物質ファミリー
|
SI2178865T1
(sl)
|
2007-07-19 |
2015-11-30 |
Lundbeck, H., A/S |
5-členski heterociklični amidi in sorodne spojine
|
WO2009023509A2
(fr)
|
2007-08-09 |
2009-02-19 |
Vertex Pharmaceuticals Incorporated |
Combinaisons thérapeutiques utiles pour traiter les maladies liées au cftr
|
NZ583420A
(en)
|
2007-08-24 |
2012-06-29 |
Vertex Pharma |
Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
|
CA2699382C
(fr)
|
2007-09-14 |
2016-05-10 |
Vertex Pharmaceuticals Incorporated |
Modulateurs du regulateur de la conductance transmembranaire de la mucoviscidose
|
JP2010540417A
(ja)
|
2007-09-14 |
2010-12-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミドの固体形態
|
JP2011502133A
(ja)
|
2007-11-02 |
2011-01-20 |
メシルジーン インコーポレイテッド |
ヒストンデアセチラーゼの阻害剤
|
EP3012250B1
(fr)
|
2007-11-16 |
2017-11-08 |
Vertex Pharmaceuticals Incorporated |
Modulateurs d'isoquinoleine de transporteurs de cassette de liaison a l'atp
|
CA2706536C
(fr)
|
2007-11-22 |
2016-04-19 |
Tadaaki Sugama |
Forme amorphe de compose heterocyclique, dispersion solide et preparation pharmaceutique comprenant chacune ladite forme amorphe et procede de production de ladite forme amorphe
|
US8507534B2
(en)
|
2007-12-07 |
2013-08-13 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
US20100036130A1
(en)
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
SI2639222T1
(sl)
|
2007-12-07 |
2016-12-30 |
Vertex Pharmaceuticals Incorporated |
Proces za izdelavo cikloalkilkarboksiamido-piridin benzojskih kislin
|
BRPI0820681A2
(pt)
|
2007-12-07 |
2019-09-24 |
Vertex Pharma |
formulações de ácido 3-(6-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilperidin-2-il)benzoico
|
CA2709301C
(fr)
|
2007-12-13 |
2016-05-10 |
Vertex Pharmaceuticals Incorporated |
Modulateurs de regulateur de conductance transmembranaire de fibrose cystique
|
US20090247521A1
(en)
|
2007-12-28 |
2009-10-01 |
Arete Therapeutics, Inc. |
Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction
|
NZ620944A
(en)
|
2008-02-28 |
2015-02-27 |
Vertex Pharma |
Heteroaryl derivatives as cftr modulators
|
SI2615085T1
(sl)
|
2008-03-31 |
2015-11-30 |
Vertex Pharmaceuticals Incorporated |
Piridilni derivati kot cftr-modulatorji
|
JP2011520785A
(ja)
|
2008-04-16 |
2011-07-21 |
バイオリポックス エービー |
薬剤としての使用のためのビスアリール化合物
|
US20090270452A1
(en)
|
2008-04-18 |
2009-10-29 |
Arete Therapeutics, Inc. |
Use of soluble epoxide hydrolase inhibitors in the treatment of smooth muscle disorders
|
AU2009240538B2
(en)
|
2008-04-24 |
2014-08-07 |
Bristol-Myers Squibb Company |
Use of Epothilone D in treating Tau-associated diseases including Alzheimer's disease
|
US20110112193A1
(en)
|
2008-05-14 |
2011-05-12 |
Peter Nilsson |
Bis-aryl compounds for use as medicaments
|
US9334242B2
(en)
|
2008-06-16 |
2016-05-10 |
Gtx, Inc. |
Compounds for treatment of cancer
|
US9447049B2
(en)
|
2010-03-01 |
2016-09-20 |
University Of Tennessee Research Foundation |
Compounds for treatment of cancer
|
US8822513B2
(en)
|
2010-03-01 |
2014-09-02 |
Gtx, Inc. |
Compounds for treatment of cancer
|
US20100256184A1
(en)
|
2008-08-13 |
2010-10-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
CA2733908C
(fr)
|
2008-08-13 |
2017-05-30 |
Vertex Pharmaceuticals Incorporated |
Composition pharmaceutique renfermant une dispersion solide de n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoqsinolin e-3-carboxamide
|
US8895781B2
(en)
|
2008-09-04 |
2014-11-25 |
Georgetown University |
Transition metal-catalyzed C—H amination using unactivated amines
|
AR073578A1
(es)
|
2008-09-15 |
2010-11-17 |
Priaxon Ag |
Pirrolidin-2-onas
|
AU2009296271A1
(en)
|
2008-09-29 |
2010-04-01 |
Vertex Pharmaceuticals Incorporated |
Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
WO2010048149A2
(fr)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
|
US20110257223A1
(en)
*
|
2008-10-23 |
2011-10-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
|
JP5645835B2
(ja)
|
2008-10-23 |
2014-12-24 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
N−(4−(7−アザビシクロ[2.2.1]ヘプタン−7−イル)−2−(トリフルオロメチル)フェニル)−4−オキソ−5−(トリフルオロメチル)−1,4−ジヒドロキノリン−3−カルボキサミドの固体形態
|
US8513282B2
(en)
*
|
2008-10-23 |
2013-08-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
CA2742042A1
(fr)
|
2008-10-23 |
2010-04-29 |
Vertex Pharmaceuticals Incorporated |
Modulateurs du regulateur de la conductance transmembranaire de la mucoviscidose
|
UA104876C2
(uk)
|
2008-11-06 |
2014-03-25 |
Вертекс Фармасьютікалз Інкорпорейтед |
Модулятори atф-зв'язувальних касетних транспортерів
|
CN102272127A
(zh)
|
2008-11-06 |
2011-12-07 |
弗特克斯药品有限公司 |
Atp-结合盒转运蛋白调节剂
|
US20120165304A1
(en)
|
2008-11-27 |
2012-06-28 |
Boehringer Ingelheim International Gmbh |
6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
MX2011005896A
(es)
|
2008-12-03 |
2011-09-29 |
Presidio Pharmaceuticals Inc |
Inhibidores de hcv ns5a.
|
JP5699090B2
(ja)
|
2008-12-30 |
2015-04-08 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
|
US8946419B2
(en)
|
2009-02-23 |
2015-02-03 |
Mallinckrodt Llc |
(+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
|
WO2010104306A2
(fr)
|
2009-03-07 |
2010-09-16 |
주식회사 메디젠텍 |
Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme
|
ES2683633T3
(es)
|
2009-03-20 |
2018-09-27 |
Vertex Pharmaceuticals Incorporated |
Moduladores de regulador de conductancia transmembrana de la fibrosis quística
|
KR101955863B1
(ko)
|
2009-03-20 |
2019-03-07 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
|
GB0905641D0
(en)
|
2009-04-01 |
2009-05-13 |
Serodus As |
Compounds
|
CN102428087B
(zh)
|
2009-04-16 |
2015-06-17 |
卡洛斯三世国家癌症研究中心基金会 |
用作激酶抑制剂的咪唑并吡嗪类化合物
|
WO2011005355A1
(fr)
|
2009-05-07 |
2011-01-13 |
Achaogen, Inc. |
Combinaisons comprenant un inhibiteur de lpxc et un antibiotique à utiliser dans le traitement d'infections induites par des bactéries à gram négatif
|
JP5685203B2
(ja)
|
2009-05-29 |
2015-03-18 |
ラクオリア創薬株式会社 |
カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
|
EP2264012A1
(fr)
|
2009-06-03 |
2010-12-22 |
Bayer CropScience AG |
Hétéroarylamidine et son utilisation en tant que fongicide
|
KR101256018B1
(ko)
|
2009-08-20 |
2013-04-18 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
|
TW201111379A
(en)
|
2009-09-09 |
2011-04-01 |
Vifor Int Ag |
Novel thiazole-and oxazole-hepcidine-antagonists
|
BR112012006031A2
(pt)
|
2009-09-17 |
2019-09-24 |
Vertex Pharma |
processo para preparação de compostos azabicíclicos.
|
US9334230B2
(en)
|
2009-09-18 |
2016-05-10 |
Nanyang Technological University |
Process of forming an amide
|
CN102665715A
(zh)
|
2009-10-22 |
2012-09-12 |
沃泰克斯药物股份有限公司 |
治疗囊性纤维化和其他慢性疾病的组合物
|
CN102666546B
(zh)
|
2009-10-23 |
2015-09-09 |
沃泰克斯药物股份有限公司 |
N-(4-(7-氮杂双环[2.2.1]庚-7-基)-2-(三氟甲基)苯基)-4-氧代-5-(三氟甲基)-1,4-二氢喹啉-3-甲酰胺的固体形式
|
BR112012009583A2
(pt)
|
2009-10-23 |
2015-09-29 |
Vertex Pharma |
processo para preparação de moduladores de regulador de condutância de transmembrana de fibrose cística
|
WO2011094890A1
(fr)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
|
WO2011115892A1
(fr)
|
2010-03-15 |
2011-09-22 |
Griffin Patrick R |
Modulateurs des récepteurs orphelins liés au récepteur de l'acide rétinoïque
|
EP2547658A1
(fr)
|
2010-03-19 |
2013-01-23 |
Vertex Pharmaceuticals Incorporated |
Formes solides de n-[2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
US8802868B2
(en)
*
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
US20110251253A1
(en)
*
|
2010-03-25 |
2011-10-13 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
|
PL3150198T3
(pl)
|
2010-04-07 |
2022-01-17 |
Vertex Pharmaceuticals Incorporated |
Kompozycje farmaceutyczne kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksamido)-3-metylopirydyn-2-ylo)benzoesowego i ich podawanie
|
CA2795748C
(fr)
|
2010-04-07 |
2020-12-08 |
Vertex Pharmaceuticals Incorporated |
Formes solides de l'acide 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yle) cyclopropane carboxamido)-3-methylpyridin-2-yle) benzoique
|
NZ603042A
(en)
*
|
2010-04-22 |
2015-02-27 |
Vertex Pharma |
Pharmaceutical compositions comprising cftr modulators and administrations thereof
|
EP2560651A1
(fr)
*
|
2010-04-22 |
2013-02-27 |
Vertex Pharmaceuticals Incorporated |
Compositions pharmaceutiques et leurs administrations
|
AU2011242454A1
(en)
*
|
2010-04-22 |
2012-11-08 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
EP3045452A1
(fr)
*
|
2010-04-22 |
2016-07-20 |
Vertex Pharmaceuticals Inc. |
Procédé de production de composés cycloalkyle-carboxamide-indole
|
EP2386606B1
(fr)
|
2010-04-30 |
2018-03-21 |
Total Marketing Services |
Utilisation de dérivés organogelateurs dans des compositions bitumineuses pour améliorer leur résistance aux agressions chimiques
|
TW201202250A
(en)
|
2010-05-20 |
2012-01-16 |
Vertex Pharma |
Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
|
SI2571506T1
(sl)
|
2010-05-20 |
2017-12-29 |
Cempra Pharmaceuticals, Inc. |
Postopki za pripravo makrolidov in ketolidov ter njihovih intermediatov
|
WO2011146901A1
(fr)
|
2010-05-20 |
2011-11-24 |
Vertex Pharmaceuticals Incorporated |
Compositions pharmaceutiques et leurs administrations
|
US8563593B2
(en)
*
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
US20120149708A1
(en)
|
2010-06-17 |
2012-06-14 |
George Mason University |
Modulators of viral transcription, and methods and compositions therewith
|
UA110113C2
(xx)
|
2010-07-29 |
2015-11-25 |
|
Біциклічні азагетероциклічні карбоксаміди
|
WO2012016133A2
(fr)
|
2010-07-29 |
2012-02-02 |
President And Fellows Of Harvard College |
Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
|
CN103153287A
(zh)
*
|
2010-08-23 |
2013-06-12 |
弗特克斯药品有限公司 |
(R)-1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)-N-(1-(2,3-二羟基丙基)-6-氟-2-(1-羟基-2-甲基丙-2-基)-1H-吲哚-5-基)环丙烷甲酰胺的药物组合物及其施用
|
JP2013536251A
(ja)
|
2010-08-27 |
2013-09-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
薬学的組成物およびその投与
|
WO2012049555A1
(fr)
|
2010-10-13 |
2012-04-19 |
Lupin Limited |
Composés spirocycliques en tant que modulateurs de canaux sodiques dépendants du voltage
|
EP2630136A1
(fr)
|
2010-10-21 |
2013-08-28 |
Universität des Saarlandes |
Inhibiteurs sélectifs de cyp11b1 pour le traitement de maladies dépendantes du cortisol
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
WO2012079583A1
(fr)
|
2010-12-15 |
2012-06-21 |
Aarhus Universitet |
Système permettant la libération contrôlée de co gazeux pour réactions de carbonylation
|
WO2012116135A2
(fr)
|
2011-02-24 |
2012-08-30 |
Emory University |
Compositions antagonistes de noggine pour ossification et procédés associés à celles-ci
|
US9464065B2
(en)
|
2011-03-24 |
2016-10-11 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
CN102731492B
(zh)
|
2011-03-30 |
2016-06-29 |
江苏恒瑞医药股份有限公司 |
环己烷类衍生物、其制备方法及其在医药上的应用
|
HUE047354T2
(hu)
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
US8945605B2
(en)
|
2011-06-07 |
2015-02-03 |
Parion Sciences, Inc. |
Aerosol delivery systems, compositions and methods
|
WO2013005057A1
(fr)
|
2011-07-07 |
2013-01-10 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Nouveaux composés
|
KR102527562B1
(ko)
|
2011-09-09 |
2023-05-03 |
랜티우스 메디컬 이메징, 인크. |
영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
|
WO2013038381A1
(fr)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Dérivés d'amide pyridine/pyrazine
|
WO2013038373A1
(fr)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Dérivés pyrimidinamides
|
US9056867B2
(en)
|
2011-09-16 |
2015-06-16 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
WO2013038378A1
(fr)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Dérivés pyridinamides
|
ES2558457T3
(es)
|
2011-09-16 |
2016-02-04 |
Novartis Ag |
Compuestos heterocíclicos para el tratamiento de fibrosis quística
|
GB201116559D0
(en)
|
2011-09-26 |
2011-11-09 |
Univ Leuven Kath |
Novel viral replication inhibitors
|
AU2012332225A1
(en)
|
2011-11-02 |
2014-05-15 |
Vertex Pharmaceuticals Incorporated |
Use of (N- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating CFTR mediated diseases
|
US20140127901A1
(en)
*
|
2012-11-08 |
2014-05-08 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Low-k damage free integration scheme for copper interconnects
|
AU2012335714B2
(en)
*
|
2011-11-08 |
2017-04-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
WO2013086131A1
(fr)
|
2011-12-06 |
2013-06-13 |
The Trustees Of The University Of Pennsylvania |
Inhibiteurs ciblant la grippe a pharmacorésistante
|
US8772541B2
(en)
|
2011-12-15 |
2014-07-08 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
|
EP2606726A1
(fr)
|
2011-12-21 |
2013-06-26 |
Bayer CropScience AG |
Dérivés de trifluoroéthylsulfure substitués par du N-arylamidine en tant qu'acaricides et insecticides
|
US20130186801A1
(en)
|
2012-01-25 |
2013-07-25 |
Vertex Pharmaceuticals Incorporated |
Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
IL265430B2
(en)
|
2012-02-27 |
2024-08-01 |
Vertex Pharma |
Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
|
US9217050B2
(en)
|
2012-04-03 |
2015-12-22 |
3M Innovative Properties Company |
Crosslinkable composition comprising photobase generators
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
US8888905B2
(en)
|
2012-04-26 |
2014-11-18 |
Xerox Corporation |
Fast crystallizing crystalline-amorphous ink compositions and methods for making the same
|
CA2813472A1
(fr)
|
2012-04-26 |
2013-10-26 |
Xerox Corporation |
Encres amorphes cristallines a solidification rapide
|
US20130284054A1
(en)
|
2012-04-26 |
2013-10-31 |
Xerox Corporation |
Rapid solidifying crystalline-amorphous inks
|
US9228101B2
(en)
|
2012-04-26 |
2016-01-05 |
Xerox Corporation |
Rapidly crystallizing phase change inks and methods for forming the same
|
US9528016B2
(en)
|
2012-04-26 |
2016-12-27 |
Xerox Corporation |
Phase change inks comprising crystalline amides
|
GB2502624A
(en)
|
2012-06-01 |
2013-12-04 |
Univ East Anglia |
Phosphoramide and phosphoramide-based catalysts and their use in intermolecular aziridination
|
EP2859005B1
(fr)
|
2012-06-08 |
2018-10-31 |
Massachusetts Institute of Technology |
Palladacycles de type sulfonate de palladium à ligand phosphine
|
CA2874851A1
(fr)
|
2012-06-08 |
2013-12-12 |
Vertex Pharmaceuticals Incorporated |
Compositions pharmaceutiques pour le traitement des troubles a mediation par cftr
|
FR2992317B1
(fr)
|
2012-06-22 |
2016-05-13 |
Diverchim |
Procede de preparation de peptides chiraux
|
WO2014002106A1
(fr)
|
2012-06-25 |
2014-01-03 |
Cadila Healthcare Limited |
Nouveaux composés pour le traitement de la dyslipidémie et de maladies associées
|
US20150209448A1
(en)
|
2012-07-12 |
2015-07-30 |
Proqr Therapeutics N.V. |
Exon replacement with stabilized artificial rnas
|
DK3103872T3
(en)
|
2012-07-12 |
2018-10-22 |
Proqr Therapeutics Ii Bv |
OLIGONUCLEOTIDES TO MAKE A CHANGE IN THE SEQUENCE OF A TARGET RNA MOLECULE IN A LIVING CELL
|
AR092857A1
(es)
|
2012-07-16 |
2015-05-06 |
Vertex Pharma |
Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
|
AU2013318206B2
(en)
|
2012-09-20 |
2018-07-26 |
Temple University - Of The Commonwealth System Of Higher Education |
Substituted alkyl diaryl derivatives, methods of preparation and uses
|
CN104769465A
(zh)
|
2012-10-29 |
2015-07-08 |
柯尼卡美能达株式会社 |
相位差膜、圆偏振片和图像显示装置
|
BR112015009913B1
(pt)
|
2012-11-02 |
2023-04-11 |
Vertex Pharmaceuticals Incorporated |
Comprimido compreendendo composto cristalino e dispersão sólida de composto substancialmente amorfo, seu processo de preparação, kit e método de preparação de um grânulo compreendendo composto cristalino e dispersão sólida de composto substancialmente amorfo
|
WO2014078479A2
(fr)
|
2012-11-14 |
2014-05-22 |
The Board Of Regents Of The University Of Texas System |
Inhibition de l'hétérodimérisation de hif-2α avec hif1β (arnt)
|
JP6146990B2
(ja)
|
2012-11-16 |
2017-06-14 |
コンサート ファーマシューティカルズ インコーポレイテッド |
重水素化されたcftr増強物質
|
BR112015011441A2
(pt)
|
2012-11-20 |
2017-07-11 |
Merial Inc |
composições e compostos antihelmínticos e métodos de usos dos mesmos
|
ITMI20122065A1
(it)
|
2012-12-03 |
2014-06-04 |
Univ Padova |
Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
|
WO2014086934A1
(fr)
|
2012-12-05 |
2014-06-12 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Diagnostic de fibrose kystique
|
EP2928532A4
(fr)
|
2012-12-07 |
2016-06-29 |
Parion Sciences Inc |
Canule nasale pour la distribution de médicaments en aérosol
|
US20140221424A1
(en)
|
2013-01-30 |
2014-08-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for use in the treatment of cystic fibrosis
|
US9452139B2
(en)
|
2013-03-14 |
2016-09-27 |
Novartis Ag |
Respirable agglomerates of porous carrier particles and micronized drug
|
US20140296164A1
(en)
|
2013-03-29 |
2014-10-02 |
Calista Therapeutics, Inc. |
Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand
|
LU92578B1
(fr)
|
2013-05-07 |
2014-12-15 |
Galapagos Nv |
Nouveaux composés et compostions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose
|
AU2014268477A1
(en)
|
2013-05-24 |
2015-11-12 |
The California Institute For Biomedical Research |
Compounds for treatment of drug resistant and persistent tuberculosis
|
JP2014232188A
(ja)
|
2013-05-29 |
2014-12-11 |
コニカミノルタ株式会社 |
セルロースアシレートフィルム、円偏光板及び画像表示装置
|
WO2014210159A1
(fr)
|
2013-06-26 |
2014-12-31 |
Proteostasis Therapeutics, Inc. |
Procédés de modulation de l'activité de cftr
|
AU2014304562B8
(en)
|
2013-08-08 |
2018-07-05 |
Galapagos Nv |
Thieno[2,3-c]pyrans as CFTR modulators
|
ES2716092T3
(es)
|
2013-09-12 |
2019-06-10 |
Inst Nat Sante Rech Med |
Métodos y composiciones farmacéuticas para el tratamiento de fibrosis quística
|
CA2924527C
(fr)
|
2013-09-20 |
2022-07-12 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Composes destines au traitement du cancer de la prostate
|
US9353078B2
(en)
|
2013-10-01 |
2016-05-31 |
New York University |
Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof
|
WO2015054337A1
(fr)
|
2013-10-09 |
2015-04-16 |
Emory University |
Catalyseurs de couplage hétérocyclique et procédés associés à ceux-ci
|
JP6963896B2
(ja)
|
2013-11-12 |
2021-11-10 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Cftr媒介性疾患の処置のための医薬組成物を調製する方法
|
KR20150062652A
(ko)
|
2013-11-29 |
2015-06-08 |
삼성전자주식회사 |
초음파 감응성 리포좀, 그를 포함한 약제학적 조성물 및 그를 이용하여 개체의 체내에 활성제를 전달하는 방법
|
CN106061480B
(zh)
|
2013-12-30 |
2020-02-28 |
莱福斯希医药公司 |
治疗性抑制性化合物
|
US20170029366A1
(en)
|
2014-03-07 |
2017-02-02 |
The Johns Hopkins University |
Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
|
JP2015172005A
(ja)
|
2014-03-11 |
2015-10-01 |
国立大学法人 東京大学 |
鉄触媒によるカップリング化合物の製造方法
|
CA2942387A1
(fr)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Composes, compositions et procedes pour augmenter l'activite cftr
|
CA2942386A1
(fr)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Composes, compositions et procedes pour augmenter l'activite du cftr
|
HRP20230709T1
(hr)
|
2014-04-15 |
2023-10-13 |
Vertex Pharmaceuticals Incorporated |
Farmaceutski pripravci za liječenje bolesti povezanih s regulatorom provodljivosti transmembrane cistične fibroze
|
CA2947982C
(fr)
|
2014-05-08 |
2022-11-29 |
Phasebio Pharmaceuticals, Inc. |
Procedes et compositions pour le traitement de la fibrose kystique
|
JP5932881B2
(ja)
*
|
2014-05-08 |
2016-06-08 |
株式会社フジクラ |
マルチコアファイバ及びそのマルチコアファイバの製造方法
|
EP3142701B1
(fr)
|
2014-05-12 |
2018-06-27 |
Verona Pharma PLC |
Nouveau traitement
|
PT3142637T
(pt)
|
2014-05-16 |
2020-10-15 |
Olaplex Inc |
Formulações e métodos de tratamento de queratina
|
NZ726874A
(en)
|
2014-05-19 |
2018-03-23 |
Merial Inc |
Anthelmintic compounds
|
WO2015187905A1
(fr)
|
2014-06-05 |
2015-12-10 |
Merck Patent Gmbh |
Nouveaux dérivés de quinoléine et leur utilisation dans des maladies neurodégénératives
|
WO2015196071A1
(fr)
|
2014-06-19 |
2015-12-23 |
Proteostasis Therapeutics, Inc. |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
CA2957790A1
(fr)
|
2014-08-13 |
2016-02-18 |
Akeso Biomedical, Inc. |
Composes et compositions antimicrobiens ainsi que leurs utilisations
|
GB201415381D0
(en)
|
2014-08-29 |
2014-10-15 |
Algipharma As |
Inhalable powder formulations of alginate oligomers
|
US10266526B2
(en)
|
2014-09-10 |
2019-04-23 |
Epizyme, Inc. |
Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
|
US11324827B2
(en)
|
2014-10-01 |
2022-05-10 |
Xiamen Sinopeg Biotech Co., Ltd. |
Multifunctionalized polyethylene glycol derivative and preparation method therefor
|
WO2016050209A1
(fr)
|
2014-10-01 |
2016-04-07 |
厦门赛诺邦格生物科技有限公司 |
Dérivé de polyéthylèneglycol hétérofonctionalisé, procédé de préparation et substance d'origine biologique
|
WO2016050208A1
(fr)
|
2014-10-01 |
2016-04-07 |
厦门赛诺邦格生物科技有限公司 |
Substance d'origine biologique modifiée par un dérivé du polyéthylèneglycol multifonctionnalisé
|
CN104725628B
(zh)
|
2014-10-01 |
2018-04-17 |
厦门赛诺邦格生物科技股份有限公司 |
一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
|
US9855249B2
(en)
|
2014-10-02 |
2018-01-02 |
Flatley Discovery Lab, Llc |
Isoxazole compounds and methods for the treatment of cystic fibrosis
|
KR20170095814A
(ko)
|
2014-10-06 |
2017-08-23 |
플랫틀리 디스커버리 랩, 엘엘씨 |
트라이아졸로피리딘 화합물 및 낭성 섬유증의 치료 방법
|
UA125245C2
(uk)
|
2014-10-06 |
2022-02-09 |
Вертекс Фармасьютикалз Інкорпорейтед |
Модулятори регулятора трансмембранної провідності при муковісцидозі
|
AU2015330923B2
(en)
|
2014-10-07 |
2020-03-12 |
Vertex Pharmaceuticals Incorporated |
Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
|
EP3204010A1
(fr)
|
2014-10-08 |
2017-08-16 |
Nivalis Therapeutics, Inc. |
Méthodes de traitement de la mucoviscidose
|
US20160108406A1
(en)
|
2014-10-08 |
2016-04-21 |
University Of Iowa Research Foundation |
Method of regulating cftr expression and processing
|
GB201418892D0
(en)
|
2014-10-23 |
2014-12-10 |
Proqr Therapeutics B V |
DNA editing
|
EP3212201B1
(fr)
|
2014-10-28 |
2022-10-19 |
BCI Pharma |
Inhibiteurs de la kinase nucléoside
|
AU2015339196A1
(en)
|
2014-10-31 |
2017-05-11 |
Abbvie S.A.R.L. |
Substituted tetrahydropyrans and method of use
|
LT3212189T
(lt)
|
2014-10-31 |
2020-11-25 |
Abbvie Overseas S.A R.L. |
Pakeisti chromanai ir naudojimo būdas
|
WO2016086015A1
(fr)
|
2014-11-25 |
2016-06-02 |
University Of Rochester |
Catalyseurs à base de myoglobine pour réactions de transfert de carbène
|
WO2016086136A1
(fr)
|
2014-11-26 |
2016-06-02 |
Catabasis Pharmaceuticals, Inc. |
Conjugués de cystéamine d'acide gras de modulateurs de cftr et leur utilisation dans le traitement de troubles médicaux
|
MA41031A
(fr)
|
2014-11-26 |
2017-10-03 |
Catabasis Pharmaceuticals Inc |
Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
|
MA41253A
(fr)
|
2014-12-23 |
2017-10-31 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
CA2971850A1
(fr)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derives d'amides 5-phenyl- ou 5-heteroarylthiazol-2-carboxyliques servant au traitement, entre autres, de la fibrose cystique
|
WO2016105468A1
(fr)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Dérivés de 3-hétéroarylisoxazol-5-amide carboxylique utiles dans le traitement, entre autres, d'une fibrose kystique
|
CA2971855A1
(fr)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derives d'amide 5-(hetero)arylpyrazol-3-carboxylique ou d'amide 1-(hetero)aryltriazol-4-carboxylique utiles pour le traitement, entre autres, de la fibrose kystique
|
CN107406488B
(zh)
|
2014-12-24 |
2021-08-31 |
凯思生物技术公司 |
用于治疗呼吸系统疾病的新型PI3Kγ抑制剂肽
|
US10167278B2
(en)
|
2014-12-31 |
2019-01-01 |
Auspex Pharmaceuticals, Inc. |
Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator
|
CN105753814A
(zh)
|
2015-01-01 |
2016-07-13 |
成都贝斯凯瑞生物科技有限公司 |
取代氮杂环衍生物及其应用
|
US20180147187A1
(en)
|
2015-01-12 |
2018-05-31 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
US10196384B2
(en)
|
2015-03-31 |
2019-02-05 |
Vertex Pharmaceuticals (Europe) Limited |
Deuterated CFTR modulators
|